XOMA Royalty (NASDAQ:XOMA) Shares Cross Above Two Hundred Day Moving Average - Here's What Happened

Shares of XOMA Royalty Corporation (NASDAQ:XOMA - Get Free Report) crossed above its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $24.29 and traded as high as $26.33. XOMA Royalty shares last traded at $26.22, with a volume of 158,454 shares traded.

Analysts Set New Price Targets

XOMA has been the subject of several research analyst reports. HC Wainwright reaffirmed a "buy" rating and set a $104.00 price target on shares of XOMA Royalty in a research report on Wednesday, May 28th. Benchmark initiated coverage on shares of XOMA Royalty in a research report on Thursday, April 17th. They set a "buy" rating and a $35.00 price target for the company. Finally, Wall Street Zen raised shares of XOMA Royalty from a "hold" rating to a "buy" rating in a research report on Saturday, June 14th.

XOMA Royalty Trading Up 5.2%

The company has a quick ratio of 5.54, a current ratio of 5.54 and a debt-to-equity ratio of 1.18. The firm's 50 day simple moving average is $24.62 and its 200-day simple moving average is $24.31. The company has a market capitalization of $330.25 million, a PE ratio of -23.99 and a beta of 0.94.

XOMA Royalty (NASDAQ:XOMA - Get Free Report) last released its quarterly earnings data on Tuesday, May 13th. The biotechnology company reported $0.06 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.26) by $0.32. XOMA Royalty had a negative net margin of 13.04% and a negative return on equity of 12.43%. The company had revenue of $15.91 million during the quarter, compared to the consensus estimate of $6.75 million. As a group, equities research analysts anticipate that XOMA Royalty Corporation will post -1.41 EPS for the current year.

Insider Activity

In other news, CIO Bradley Sitko bought 2,000 shares of the firm's stock in a transaction dated Monday, April 7th. The stock was acquired at an average cost of $24.70 per share, for a total transaction of $49,400.00. Following the completion of the purchase, the executive now owns 5,045 shares of the company's stock, valued at $124,611.50. This trade represents a 65.68% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Joseph M. Limber bought 5,243 shares of the firm's stock in a transaction dated Monday, April 7th. The stock was purchased at an average price of $25.60 per share, with a total value of $134,220.80. Following the completion of the purchase, the director now directly owns 10,000 shares of the company's stock, valued at approximately $256,000. This trade represents a 110.22% increase in their position. The disclosure for this purchase can be found here. Over the last three months, insiders bought 25,178 shares of company stock worth $636,300. 7.20% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in XOMA. Nuveen Asset Management LLC raised its holdings in shares of XOMA Royalty by 3.8% during the fourth quarter. Nuveen Asset Management LLC now owns 14,363 shares of the biotechnology company's stock worth $377,000 after purchasing an additional 527 shares during the period. New York State Common Retirement Fund raised its holdings in shares of XOMA Royalty by 51.2% during the fourth quarter. New York State Common Retirement Fund now owns 2,362 shares of the biotechnology company's stock worth $62,000 after purchasing an additional 800 shares during the period. Eversept Partners LP raised its holdings in shares of XOMA Royalty by 1.2% during the fourth quarter. Eversept Partners LP now owns 95,417 shares of the biotechnology company's stock worth $2,508,000 after purchasing an additional 1,128 shares during the period. Wells Fargo & Company MN raised its holdings in shares of XOMA Royalty by 38.0% during the fourth quarter. Wells Fargo & Company MN now owns 4,300 shares of the biotechnology company's stock worth $113,000 after purchasing an additional 1,183 shares during the period. Finally, Charles Schwab Investment Management Inc. raised its holdings in shares of XOMA Royalty by 5.8% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 23,113 shares of the biotechnology company's stock worth $607,000 after purchasing an additional 1,276 shares during the period. 95.92% of the stock is currently owned by institutional investors.

About XOMA Royalty

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.